by Natasha Yates, The Conversation Credit: www.shutterstock.com I waited for hours in emergency last night with this dreadful headache, but eventually gave up and left. Should I have kept waiting at the hospital? This is a surprisingly common scenario I encounter as a general practitioner. If you’re wondering how bad your headache needs to be to go...
Steve Cimino Most cases of new daily persistent headache (NDPH) are moderate to severe and many feature characteristics often associated with migraine, according to a new retrospective chart review. “Future prospective studies are needed to better understand this disabling disorder,” wrote Randolph W. Evans, MD, of Baylor College of Medicine of Houston, and Dana P. Turner, PhD, of Massachusetts General...
Aura is a sensory disturbance that can occur before a migraine headache. A person may see flashing lights, zigzag lines, or colored spots. In some cases, people experience aura without a headache. This is known as “silent migraine.” According to the American Migraine Foundation, around 25–30% of people with migraines experience aura. The symptoms usually...
Tara Haelle June 09, 2021 Patients overwhelmingly found telemedicine care for headache a satisfactory and beneficial experience during the COVID-19 pandemic, according to a study presented at the American Headache Society’s 2021 annual meeting. Most patients who used telemedicine said they would like to continue using it after the pandemic, though the study also revealed barriers to care...
By Osman Shabir, M.Sc.Reviewed by Dr. Jennifer Logan, MD, MPH Headaches can occur due to a variety of reasons, with most of them not being serious. Whilst there are well over 200 types of headache, there are typically two major types of headaches: primary (90%), in which the headache is a ‘headache-condition’ in itself (for example, migraine...
“I believe that the Relivion device from Neurolief has great potential to improve acute migraine therapy,” said Alan Rapoport, M.D., clinical professor of neurology at The David Geffen School of Medicine at UCLA, past president of the International Headache Society (IHS), and the founder and director-emeritus of The New England Center for Headache. “Not only...
OREGON HEALTH & SCIENCE UNIVERSITY An early assessment reveals that a newly approved drug to treat migraines does not seem effective among patients who suffer from high-frequency migraines. The findings will be presented this week during the 61st annual scientific meeting of the American Headache Society in Philadelphia. Clinicians at OHSU in Portland, Oregon, conducted...
Peter J. Goadsby, M.D., Ph.D., from King’s College London, and colleagues enrolled patients who had at least one attack every other day, a total of at least four attacks, or no more than eight attacks per day during a baseline assessment. Recruitment was halted before the planned sample size of 162 patients was reached because too few volunteers...
Episodic cluster headaches are “an extremely painful and often debilitating condition,” the FDA’s Dr. Eric Bastings noted in an agency news release. He’s deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. Cluster headaches occur in quick sequence, “often at the same time(s) of the day, for several weeks...
Travelers’ diarrhea affects an estimated 10 to 40 percent of travelers worldwide each year, according to an FDA press release. The highest-risk destinations are most of Asia, the Middle East, Africa, Mexico, and Central and South America. (HealthDay)—The U.S. Food and Drug Administration on Friday announced it has approved Aemcolo (rifamycin), an antibacterial drug indicated...
